The short version of lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
According to The Economist, the US typically has "two or three American warships and Coast Guard cutters" on patrol in the southern Caribbean. As of 25 September 2025, the deployment included ten ships: the guided-missile destroyers USS Gravely, USS Stockdale and USS Jason Dunham; the amphibious assault ship USS Iwo Jima and the amphibious transport docks USS San Antonio and USS Fort Lauderdale; the guided-missile cruiser USS Lake Erie; the littoral combat ship USS Minneapolis-Saint Paul; the nuclear fast attack submarine USS Newport News, and the special operations ship MV Ocean Trader. According to the Financial Times, "Five of the eight vessels are equipped with Tomahawk missiles, which can hit land targets." On 25 September, Task & Purpose reported that the US had deployed special operations ship MV Ocean Trader to the Caribbean. The Iwo Jima, Fort Lauderdale, and San Antonio of the Iwo Jima Amphibious Ready Group left Norfolk, Virginia, on 14 August, with more than 4,000 personnel, including the 22nd Marine Expeditionary Unit, with 2,200 Marines. According to the US Naval Institute this marked "the first time a US-based Amphibious Ready Group with embarked Marines has deployed since December." Historian Alan McPherson stated that the naval buildup is the largest in the region since 1965. During a surprise trip on 8 September to Puerto Rico with Joint Chiefs of Staff Chairman Dan Caine, Defense Secretary Pete Hegseth told sailors and Marines assigned to the area: "What you're doing right now – it's not training ...
== Motivation == Nature has evolved cyclic peptides for signaling and host defense. These molecules have therapeutic applications, including use as antibiotics (e.g., vancomycin, bacitracin), immunosuppressants (e.g., ciclosporin), and chemotherapeutics (e.g., romidepsin). The constrained structure of cyclic peptides compared to linear peptides can enhance potency and stability. Advances in synthetic cyclic peptide libraries and in vitro affinity-based selection methods have enabled their development as templates for drug discovery and other applications. Despite progress in identifying synthetic cyclic peptides with high affinity and selectivity, challenges remain in achieving cell permeability and metabolic stability, which continue to be areas of active research.
==== Ethiopia ==== Approximately 30% of the Ethiopian population carry an extra copy of the gene CYP2D6, and are classified as codeine ultrametabolizers. These individuals metabolize codeine to morphine at a dangerously fast rate, leading to adverse events and potentially death. As a consequence the Ethiopian Food, Medicine and Health Care Administration and Control Authority has entirely banned the use of codeine as unsafe for the general population.
Sources: en.wikipedia.org
Their reduced gametophytes developed from megaspores retained within the spore-producing organs (megasporangia) of the sporophyte, a condition known as endospory. Seeds consist of an endosporic megasporangium surrounded by one or two sheathing layers (integuments). The young sporophyte develops within the seed, which on germination splits to release it. The earliest known seed plants date from the latest Devonian Famennian stage. Following the evolution of the seed habit, seed plants diversified, giving rise to a number of now-extinct groups, including seed ferns, as well as the modern gymnosperms and angiosperms. Gymnosperms produce "naked seeds" not fully enclosed in an ovary; modern representatives include conifers, cycads, Ginkgo, and Gnetales. Angiosperms produce seeds enclosed in a structure such as a carpel or an ovary. Ongoing research on the molecular phylogenetics of living plants appears to show that the angiosperms are a sister clade to the gymnosperms.
Peppermint was first identified in Hertfordshire, England, by a Dr. Eales, a discovery which John Ray published 1696 in the second edition of his book Synopsis Methodica Stirpium Britannicarum. He initially gave it the name Mentha spicis brevioribus et habitioribus, foliis Mentha fusca, sapore fervido piperis and later in his 1704 volume Historia Plantarum he called it Mentha palustris or Peper–Mint. The plant was then added to the London Pharmacopoeia under the name Mentha piperitis sapore in 1721. It was given the name Mentha piperita in 1753 by Carl Linnaeus in his Species Plantarum Volume 2. Linnaeus treated peppermint as a species, but it is now agreed to be a hybrid between Mentha aquatica and Mentha spicata, with M. spicata itself also being considered by some authors to be a hybrid between Mentha longifolia and Mentha suaveolens. Peppermint is a herbaceous, rhizomatous, perennial plant that grows to be 30–90 cm (12–35 in) tall, with smooth stems, square in cross section. The rhizomes are wide-spreading and fleshy, and bear fibrous roots. The leaves can be 4–9 cm (1.6–3.5 in) long and 1.5–4 cm (0.59–1.57 in) broad. They are dark green with reddish veins, with an acute apex and coarsely toothed margins. The leaves and stems are usually slightly fuzzy. The flowers are purple, 6–8 mm (0.24–0.31 in) long, with a four-lobed corolla about 5 mm (0.20 in) diameter; they are produced in whorls (verticillasters) around the stem, forming thick, blunt spikes. Flowering season lasts from mid- to late summer.
== Adverse effects == Dutasteride has overall been found to be well tolerated in studies of both men and women, producing minimal side effects. Adverse effects include headache and gastrointestinal discomfort. Isolated reports of menstrual changes, acne, and dizziness also exist. A small risk of sexual side effects has been documented in men taking the drug during the first few months of therapy. The FDA added a black-box warning to dutasteride in 2011 describing an increased risk of high-grade prostate cancer in those who take the drug. No direct mechanistic link between 5α-reductase inhibitors and prostate cancer has been established. This is not due to a direct link between dutasteride or other 5α-reductase inhibitors and cancer per se, but rather that those who take 5α-reductase inhibitors may have a decrease in prostate-specific antigen (PSA) levels, and therefore increases in PSA (which are an indicator of possible cancer) may be masked in those who take the drug. This is thought to delay cancer diagnosis so that patients taking 5α-reductase inhibitors present with a higher-grade tumor at the time of diagnosis. The American Urological Association advises that increased risk for patients taking these drugs leads to higher prostate cancer-specific and all-cause mortality. The AUA also advises that this effect can be alleviated with more frequent screening and lower PSA cutoffs for diagnostic biopsies in men taking dutasteride or other 5α-reductase inhibitors. Dutasteride is known to reduce the growth and prevalence of benign prostate tumors.
Sources: en.wikipedia.org
cell physiology The study of the various biological activities and biochemical processes which sustain life inside cells, particularly (but not necessarily limited to) those related to metabolism and energy transfer, growth and reproduction, and the ordinary processes of the cell cycle.
== Commercialisation == Commercial disinfection applications remained elusive for a long time after the discovery of hypochlorous acid because the stability of its solution in water is difficult to maintain. The active compounds quickly deteriorate back into salt water, losing the solution its disinfecting capability, which makes it difficult to transport for wide use. It is less commonly used as a disinfectant compared to bleach and alcohol due to cost, despite its stronger disinfecting capabilities. Technological developments have reduced manufacturing costs and allow for manufacturing and bottling of hypochlorous acid water for home and commercial use. However, most hypochlorous acid water has a short shelf life. Storing away from heat and direct sunlight can help slow the deterioration. The further development of continuous flow electrochemical cells has been implemented in new products, allowing the commercialisation of domestic and industrial continuous flow devices for the in-situ generation of hypochlorous acid for disinfection purposes.
Other minor differences occurred along with the facelift. The range was replaced in 1980, however, the station wagon models continued in production until 1986. The FA4-series Familia/323 was available in several body variants:
== External links == Interview with Roderick MacKinnon by Harry Kroto Freeview video provided by the Vega Science Trust. Website of his lab at The Rockefeller University Ion Channel Chemistry: The Electrical System of Life Transcribed video of a May 2008 talk by MacKinnon, sponsored by the Oregon State University Libraries. Nobel Lecture by Roderick MacKinnon, 2003 Introduction to Neuroscience by Donald C.Cooper Roderick MacKinnon on Nobelprize.org
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.